El En SpA
MIL:ELN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.45
14.63
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
El En SpA
El.En.SpA operates as a holding company, which engages in the production, research and development, distribution, and sale of laser systems. The company is headquartered in Calenzano, Firenze. The company went IPO on 2000-12-11. The company controls a group of companies active in the manufacture, research, development, distribution and sale of laser equipment.The Company's range of products includes laser systems for dermatology, surgery, cosmetics, physiotherapy, dentistry and gynaecology, laser systems for cutting, marking and welding of metals, wood, plastic and glass; decoration of leather and fabrics, conservative restoration of works of art. The firm also offers accessories, after-sale services and consulting in the related areas.
El.En.SpA operates as a holding company, which engages in the production, research and development, distribution, and sale of laser systems. The company is headquartered in Calenzano, Firenze. The company went IPO on 2000-12-11. The company controls a group of companies active in the manufacture, research, development, distribution and sale of laser equipment.The Company's range of products includes laser systems for dermatology, surgery, cosmetics, physiotherapy, dentistry and gynaecology, laser systems for cutting, marking and welding of metals, wood, plastic and glass; decoration of leather and fabrics, conservative restoration of works of art. The firm also offers accessories, after-sale services and consulting in the related areas.
Profitability: Q3 was especially strong in terms of profitability, with a 3.8% increase in EBIT versus last year, driven by the medical division.
Medical Division: Medical revenue grew 4.6% in the first 9 months, or over 10% excluding the Cynosure contract and Japanese subsidiary effects, and gross margins improved significantly.
Industrial Division: Industrial revenue rose just 1.9%, with the cutting business underperforming due to delayed revenues and competitive pressures.
Cash Position: The group generated strong cash flow, with the net financial position increasing by EUR 47 million in Q3, aided by the sale of a majority stake in a Chinese subsidiary.
Guidance: Management expects to beat 2024 in both revenue and EBIT, targeting EUR 23 million in EBIT for Q4 2025.
Geographic Performance: The Italian market was a standout, with medical revenues up 27%; European markets also performed well, while U.S. industrial sales suffered from M&A-related uncertainty.
M&A Strategy: The company is exploring small, potentially accretive acquisitions mainly in medical but also industrial; transformational deals are only at early evaluation stages.
